Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year. -
A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here's what really went down.
-
Strep throat is more prevalent this year, and amoxicillin manufacturers didn't make enough of the antibiotic to go around.
-
The drug had been fast-tracked for approval under the agency's accelerated approval program, and has been available for more than a decade, despite the drugmaker's failure to prove that it works.
-
The FDA approved Narcan for sale without a prescription. The opioid overdose reversal drug would be available at pharmacies and convenience stores nationally, increasing access as opioid deaths climb.
-
Moderna is quadrupling the price of its COVID-19 vaccine when the U.S. government is no longer the exclusive buyer. Senators grilled the company's CEO on the hike and access for the uninsured.
-
Once U.S. stockpiles of COVID-19 vaccine run out, Moderna says it might charge as much as $130 per dose, but give people who lack health insurance a break. Critics say that's not enough help.
-
The Food and Drug Administration has new tools to hold drug companies accountable for promises they make about medications. But the agency has yet to show its hand in using this new power.
-
Moderna said people without insurance will be able to get its COVID vaccine at no cost after the U.S. government bows out. But patients will have to use the company's cumbersome assistance program.
-
An insulin maker is cutting its prices. Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes.
